ClinicalTrials.gg
CompletedNCT05396742Updated Jan 22, 2024Results posted

Pharmacokinetic Study of Ravulizumab Administered Subcutaneously With Recombinant Human Hyaluronidase PH20 (rHuPH20) in Healthy Adult Volunteers

A Phase 1 interventional study of Ravulizumab and rHuPH20 in Healthy, sponsored by Alexion Pharmaceuticals, Inc.. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-01-22.

Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Registered 3 years 9 months after the study started (first participant enrolled Aug 2018, registered May 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
49
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The main objectives of this study were to estimate the absolute bioavailability of ravulizumab/rHuPH20 subcutaneous (SC) and to assess the safety and tolerability of ravulizumab/rHuPH20 SC.

02

Conditions studied

  • Healthy

Keywords

  • ALXN1210
  • Pharmacokinetic
  • Pharmacodynamic
  • Safety
  • Immunogenicity
  • Ravulizumab
  • rHuPH20
03

In context

Lead sponsor

Alexion Pharmaceuticals, Inc. is the lead sponsor of 255 studies on the registry; 23 are open to participants now.

Of its 101 completed or terminated interventional studies of FDA-regulated products, 75 (74%) have results posted.

First submitted after Alexion Pharmaceuticals, Inc. became part of AstraZeneca.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • Body weight between 60 and 90 kilogram (kg), inclusive, and within the range 18 through 29.9 kg/square meter, inclusive.
  • Negative serum pregnancy test at screening and Day -1
  • Male participants and females of must be using highly effective consisting of 2 forms of birth control (at least 1 of which must be a barrier method) while on treatment and for up to 8 months after last dose of study drug.
  • corrected using the Fridericia's formula (QTcF) ≤450 milliseconds (msec) for male participants and ≤470 msec for female participants at screening and prior to dosing on Day 1.
  • Documented vaccination with meningococcal conjugate vaccine (MCV4) at least 56 days and not more than 2 years, 4 months prior to dosing.
  • Vaccination with serogroup B meningococcal vaccine at least 56 days prior to dosing on Day 1, with a booster administered at least 28 days prior to dosing on Day 1, with at least 28 days between the first and second injections.

Key Exclusion Criteria:

  • Current or recurrent disease (for example, cardiovascular, hematological, neurological, endocrine, immunological, rheumatological, renal, hepatic or gastrointestinal or other conditions) that or could affect clinical assessments or clinical laboratory evaluations.
  • Current or relevant history of physical or psychiatric illness that are not stable or may require a change in treatment, use of prohibited therapies during the study or make the participant unlikely to fully comply with the requirements of the study or complete the study, or any condition that presents undue risk from the product or study procedures.
  • Any other significant disease or disorder which, in the opinion of the Investigator, may put the participant at risk.
  • Documented history of allergy to penicillin or cephalosporin.
  • History of significant allergic reaction (for example, anaphylaxis or angioedema) to any product (for example, food, pharmaceutical).
  • Use of prescription medications (excluding oral contraceptives) within 14 days prior to dosing on Day 1, except with prior approval of the Sponsor.
  • Regular use of nonprescription, over-the-counter medications, including herbal remedies and supplements, within 14 days prior to dosing on Day 1. Multivitamins, paracetamol (acetaminophen) ≤2 grams (g) per day, and topical skin products without significant systemic absorption are allowed.
  • Positive urine drug toxicology screen at screening or on Day -1.
  • Alcohol consumption within 48 hours prior to study drug administration or positive alcohol breath test on Day -1.
  • Donation of plasma within 7 days prior to dosing on Day 1. Donation or loss (excluding volume drawn at screening) of more than 50 milliliters (mL) of blood within 30 days prior to dosing or more than 499 mL of blood within 56 days prior to dosing on Day 1.
  • Female participants who are breastfeeding.
  • Participants who are in intimate and prolonged contact with (defined as living under the same roof or providing personal care to) people younger than 2 years of age or older than 65 years of age, or who are either or have one of the following underlying medical conditions: anatomic or functional asplenia (including sickle cell disease); congenital complement, properdin, factor D, or primary antibody deficiencies; acquired complement deficiencies (for example, those receiving eculizumab); or (HIV).
  • Participants who are one of the following:

    1. Professionals exposed to environments of greater risk for meningococcal disease
    2. Research, industrial, and clinical laboratory personnel who are routinely exposed to N meningitidis
    3. Military personnel during recruit training
    4. Daycare center workers
    5. Those living on a college or university campus
    6. Those who plan to travel during the course of the study to or have travelled to endemic areas for meningococcal meningitis (for example, India, Sub-Saharan Africa, pilgrimage to Saudi Arabia for Hajj) within 6 months prior to dosing
  • Immunization with a 28 days prior to dosing on Day 1 or planned vaccination during the course of the study (except for the vaccination planned by the study protocol). Immunization with inactivated or recombinant influenza vaccine is permitted.
  • Prior exposure to ravulizumab or eculizumab.
  • Major surgery or hospitalization within 90 days prior to dosing on Day 1.
  • History of allergy or to of ravulizumab (for example, polysorbate 80), rHuPH20, or other hyaluronidases.
  • Currently smokes >10 cigarettes daily (former smokers may be permitted to enroll at the Investigator's discretion) and is unwilling to refrain from smoking while a resident in the clinical research unit or comply with the smoking restrictions.
  • History of illicit drug abuse, history of significant alcohol abuse within 1 year prior to the screening visit, or clinical evidence of substance and/or alcohol abuse within the 2 years before screening.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
49 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Participants received a single dose of ravulizumab SC 400 (milligrams) mg .

    Drug: Ravulizumab

  • Experimental
    Cohort 2

    Participants received a single dose of ravulizumab SC 500 mg/rHuPH20 10000 units.

    Drug: Ravulizumab · Drug: rHuPH20

  • Experimental
    Cohort 3

    Participants received a single dose of ravulizumab SC 1000 mg/rHuPH20 20000 units.

    Drug: Ravulizumab · Drug: rHuPH20

  • Experimental
    Cohort 4

    Participants received a single dose of ravulizumab SC 2000 mg/rHuPH20 40000 units.

    Drug: Ravulizumab · Drug: rHuPH20

  • Experimental
    Cohort 5

    Participants received a single dose of ravulizumab intravenously (IV) 400 mg.

    Drug: Ravulizumab

Interventions

  • Solution for infusion or injection, as applicable

    Also known as: Ultomiris, ALXN1210

  • Solution for infusion

    Also known as: Recombinant human hyaluronidase PH20

06

What researchers measure

Primary outcomes

  1. Absolute Bioavailability Of Ravulizumab Subcutaneous (SC)/rHuPH20

    Dose-normalized area under the serum concentration versus time curve from 0 extrapolated to infinity (AUC0-inf) and body weight-adjusted AUC0-inf for the ravulizumab/rHuPH20 SC cohorts were compared with the 400 mg ravulizumab intravenous (IV) cohort to determine absolute bioavailability. Geometric mean ratios of the AUC0-inf parameter were calculated for each group. Absolute bioavailability is reported as the geometric mean ratio, which was defined as the ratio of geometric means for the dose-normalized AUC0-inf parameter (with and without body-weight adjustment) for the ravulizumab SC cohort divided by that for the ravulizumab IV cohort.

    Time frame: Day 1 (after first dose) to Day 200

  2. Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs)

    An AE was reported as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study drug, whether or not considered related to the study drug. Serious AEs (SAEs) were defined as any untoward medical occurrence that, at any dose resulted in death, life threatening, required hospitalization, resulted in persistent disability or incapacity, resulted in birth defect, or other situations. A summary of serious and all other non-serious AEs, regardless of causality, is located in the Reported Adverse Events module.

    Time frame: Day 1 (after first dose) up to Day 200 (including safety follow up)

Secondary outcomes

  1. Relative Bioavailability Of Ravulizumab SC/rHuPH20 Compared With Ravulizumab SC

    Dose-normalized AUC0-inf and body weight-adjusted AUC0-inf for the ravulizumab/rHuPH20 SC cohorts were compared with the 400 mg ravulizumab SC cohort to determine relative bioavailability. Geometric mean ratios of the AUC0-inf parameter were calculated for each group. Relative bioavailability is reported as the geometric mean ratio, which was defined as the ratio of the geometric means for the dose-normalized AUC0-inf parameter (with and without body-weight adjustment) for the ravulizumab/rHuPH SC cohort divided by that for the ravulizumab SC cohort.

    Time frame: Day 1 (after first dose) to Day 200

  2. Maximum Percent Change From Baseline (PCFB) In Serum Levels Of Total Complement Component 5 (C5) Concentrations

    The highest (maximum difference) mean (standard deviation \[SD\]) PCFB at up to Day 200 is reported. Baseline was defined as the last available value prior to the first drug administration. Change from Baseline was calculated as observed value minus the baseline value. PCFB was calculated as change from baseline divided by baseline multiplied by 100.

    Time frame: Baseline, Up to Day 200

  3. Maximum PCFB In Serum Levels Of Free C5 Concentrations

    The highest (maximum difference) mean (SD) PCFB at up to Day 200 is reported. Baseline was defined as the last available value prior to the first drug administration. Change from Baseline was calculated as observed value minus the baseline value. PCFB was calculated as change from baseline divided by baseline multiplied by 100.

    Time frame: Baseline, Day 200

  4. Maximum PCFB In Ex Vivo Chicken Red Blood Cell (cRBC) Hemolysis Activity

    The highest (maximum difference) mean (SD) PCFB at up to Day 200 is reported. Baseline was defined as the last available value prior to the first drug administration. Change from Baseline was calculated as observed value minus the baseline value. PCFB was calculated as change from baseline divided by baseline multiplied by 100.

    Time frame: Baseline, Up to Day 200

07

Results

Posted Jan 22, 2024

Participant flow

Eligible participants who met all inclusion and no exclusion criteria were assigned unique numbers for enrollment and randomization. Randomization was only used when cohorts were enrolled in parallel.

Participant flow — Overall Study
MilestoneCohort 1Cohort 2Cohort 3Cohort 4Cohort 5
Started71212126
Received at least 1 dose of study drug71212126
Completed71212126
Not completed00000

Outcome measures

PrimaryAbsolute Bioavailability Of Ravulizumab Subcutaneous (SC)/rHuPH20

Dose-normalized area under the serum concentration versus time curve from 0 extrapolated to infinity (AUC0-inf) and body weight-adjusted AUC0-inf for the ravulizumab/rHuPH20 SC cohorts were compared with the 400 mg ravulizumab intravenous (IV) cohort to determine absolute bioavailability. Geometric mean ratios of the AUC0-inf parameter were calculated for each group. Absolute bioavailability is reported as the geometric mean ratio, which was defined as the ratio of geometric means for the dose-normalized AUC0-inf parameter (with and without body-weight adjustment) for the ravulizumab SC cohort divided by that for the ravulizumab IV cohort.

Time frame:
Day 1 (after first dose) to Day 200
Reported as:
Geometric mean · Percent bioavailability
Absolute Bioavailability Of Ravulizumab Subcutaneous (SC)/rHuPH20
Percent bioavailabilityCohort 1Cohort 2Cohort 3Cohort 4
Dose-normalized AUC0-inf64 (44 to 92)73 (57 to 94)77 (57 to 102)84 (63 to 113)
Body weight-adjusted and dose-normalized AUC0-inf63 (46 to 85)69 (57 to 84)70 (55 to 90)81 (63 to 104)
PrimaryNumber of Participants Reporting Treatment-Emergent Adverse Events (TEAEs)

An AE was reported as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study drug, whether or not considered related to the study drug. Serious AEs (SAEs) were defined as any untoward medical occurrence that, at any dose resulted in death, life threatening, required hospitalization, resulted in persistent disability or incapacity, resulted in birth defect, or other situations. A summary of serious and all other non-serious AEs, regardless of causality, is located in the Reported Adverse Events module.

Time frame:
Day 1 (after first dose) up to Day 200 (including safety follow up)
Reported as:
Number · Participants
Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs)
ParticipantsCohort 1Cohort 2Cohort 3Cohort 4Cohort 5
TEAEs71112105
SAEs00000
Discontinuations due to TEAEs00000
Deaths00000
SecondaryRelative Bioavailability Of Ravulizumab SC/rHuPH20 Compared With Ravulizumab SC

Dose-normalized AUC0-inf and body weight-adjusted AUC0-inf for the ravulizumab/rHuPH20 SC cohorts were compared with the 400 mg ravulizumab SC cohort to determine relative bioavailability. Geometric mean ratios of the AUC0-inf parameter were calculated for each group. Relative bioavailability is reported as the geometric mean ratio, which was defined as the ratio of the geometric means for the dose-normalized AUC0-inf parameter (with and without body-weight adjustment) for the ravulizumab/rHuPH SC cohort divided by that for the ravulizumab SC cohort.

Time frame:
Day 1 (after first dose) to Day 200
Reported as:
Geometric mean · Percent bioavailability
Relative Bioavailability Of Ravulizumab SC/rHuPH20 Compared With Ravulizumab SC
Percent bioavailabilityCohort 2Cohort 3Cohort 4
Dose-normalized AUC0-inf115 (91 to 145)120 (91 to 158)132 (100 to 175)
Body weight-adjusted and dose-normalized AUC0-inf109 (90 to 134)112 (88 to 142)129 (101 to 165)
SecondaryMaximum Percent Change From Baseline (PCFB) In Serum Levels Of Total Complement Component 5 (C5) Concentrations

The highest (maximum difference) mean (standard deviation \[SD\]) PCFB at up to Day 200 is reported. Baseline was defined as the last available value prior to the first drug administration. Change from Baseline was calculated as observed value minus the baseline value. PCFB was calculated as change from baseline divided by baseline multiplied by 100.

Time frame:
Baseline, Up to Day 200
Reported as:
Mean · Percent change
Maximum Percent Change From Baseline (PCFB) In Serum Levels Of Total Complement Component 5 (C5) Concentrations
Percent changeCohort 1Cohort 2Cohort 3Cohort 4Cohort 5
Maximum Percent Change From Baseline (PCFB) In Serum Levels Of Total Complement Component 5 (C5) Concentrations92.12 ± 58.33298.68 ± 27.659107.46 ± 45.769133.48 ± 35.782112.90 ± 27.878
SecondaryMaximum PCFB In Serum Levels Of Free C5 Concentrations

The highest (maximum difference) mean (SD) PCFB at up to Day 200 is reported. Baseline was defined as the last available value prior to the first drug administration. Change from Baseline was calculated as observed value minus the baseline value. PCFB was calculated as change from baseline divided by baseline multiplied by 100.

Time frame:
Baseline, Day 200
Reported as:
Mean · Percent Change
Maximum PCFB In Serum Levels Of Free C5 Concentrations
Percent ChangeCohort 1Cohort 2Cohort 3Cohort 4Cohort 5
Maximum PCFB In Serum Levels Of Free C5 Concentrations-96.83 ± 4.783-99.48 ± 0.349-99.84 ± 0.116-99.90 ± 0.00-99.90 ± 0.00
SecondaryMaximum PCFB In Ex Vivo Chicken Red Blood Cell (cRBC) Hemolysis Activity

The highest (maximum difference) mean (SD) PCFB at up to Day 200 is reported. Baseline was defined as the last available value prior to the first drug administration. Change from Baseline was calculated as observed value minus the baseline value. PCFB was calculated as change from baseline divided by baseline multiplied by 100.

Time frame:
Baseline, Up to Day 200
Reported as:
Mean · Percent change
Maximum PCFB In Ex Vivo Chicken Red Blood Cell (cRBC) Hemolysis Activity
Percent changeCohort 1Cohort 2Cohort 3Cohort 4Cohort 5
Maximum PCFB In Ex Vivo Chicken Red Blood Cell (cRBC) Hemolysis Activity-58.07 ± 19.382-77.68 ± 23.765-80.74 ± 28.153-99.35 ± 0.684-98.52 ± 1.790

Adverse events

Collected over Day 1 (after first dose) up to Day 200 (including safety follow up). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 10/7 (0%)0/7 (0%)7/7 (100%)
Cohort 20/12 (0%)0/12 (0%)11/12 (91.7%)
Cohort 30/12 (0%)0/12 (0%)12/12 (100%)
Cohort 40/12 (0%)0/12 (0%)10/12 (83.3%)
Cohort 50/6 (0%)0/6 (0%)5/6 (83.3%)
Most frequent other events
Showing 10 of 68
Most frequent other events
EventCohort 1Cohort 2Cohort 3Cohort 4Cohort 5
Upper respiratory tract infectionInfections and infestations5/76/124/124/123/6
Vulvovaginal candidiasisInfections and infestations1/20/40/71/3—
Injection site pruritusGeneral disorders0/73/126/124/120/6
Bacterial vaginosisInfections and infestations1/20/40/70/3—
HeadacheNervous system disorders1/72/125/121/122/6
NasopharyngitisInfections and infestations2/72/123/120/120/6
Influenza like illnessGeneral disorders1/70/123/123/121/6
Medical device site reactionGeneral disorders0/70/123/120/120/6
Musculoskeletal stiffnessMusculoskeletal and connective tissue disorders0/70/123/120/121/6
Vaginal dischargeReproductive system and breast disorders0/21/40/70/3—

Baseline characteristics

The Safety Population included all participants who receive at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Cohort 1Cohort 2Cohort 3Cohort 4Cohort 5Total
Mean29.6 ± 7.4127.5 ± 5.1128.9 ± 6.9929.5 ± 7.5728.8 ± 4.7528.8 ± 6.34
Age, Customized
Age, Customized(Participants)Cohort 1Cohort 2Cohort 3Cohort 4Cohort 5Total
In utero000000
Preterm newborn infants (gestational age < 37 wks)000000
Newborns (0-27 days)000000
Infants and toddlers (28 days-23 months)000000
Children (2-11 years)000000
Adolescents (12-17 years)000000
Adults (18-64 years)7121212649
From 65-84 years000000
85 years and over000000
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1Cohort 2Cohort 3Cohort 4Cohort 5Total
Female2473016
Male5859633
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1Cohort 2Cohort 3Cohort 4Cohort 5Total
Hispanic or Latino000101
Not Hispanic or Latino6121211647
Unknown or Not Reported100001
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cohort 1Cohort 2Cohort 3Cohort 4Cohort 5Total
Asian012014
Black or African American210014
White49911336
Other111115
08

Study locations

1 site
  • Clinical Trial Site
    London, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2018 to primary completion in May 2019, 9 months.

Results were first posted in Jan 2024, 4 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 25, 2022
First posted
May 31, 2022
StartActual
Aug 9, 2018
Primary completionActual
May 21, 2019
CompletionActual
May 21, 2019
Results first posted
Jan 22, 2024
Last update
Jan 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05396742
Responsible party
Sponsor
First posted
May 31, 2022
Start date
Aug 9, 2018
Primary completion
May 21, 2019
Completion
May 21, 2019
Results posted
Jan 22, 2024
Last update
Jan 22, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ravulizumab

Start the discussion